Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

RNL Natural develops new method to detect breast cancer at ‘Stage 0’

Biotech firm RNL Natural has developed a new method of detecting breast cancer utilizing breath analyzer as early as at 'stage 0' through breath Volatile organic compounds (VOC's, a predictor of breast cancer).

Researchers at RNL organized a study of 35 women diagnosed with breast cancer and 35 healthy women not suffering from the disease and demonstrated that the breath analyzer showed and visualized distinct patterns of VOCs.

Principal investigator of the research Ra stated the trial demonstrated that screening breast cancer using breathalyser is simple, painless and cost effective.

”We are continuing to find ways to prevent further progression of diseases like breast cancer through early detection and treatment," Ra said.

The new technology’s patent is pending and will be published by the end of 2011.